This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
the prevalence of infection amongst men; the prevalence of infection amongst women; the probability of infection being passed to the male partner; the probability of infection being passed to the female partner; the probability of symptomatic disease amongst infected individuals; the average future symptom days amongst men with symptomatic disease; the average future symptom days amongst women with symptomatic disease; the relative risk of infection with regular condom use; the sensitivity and specificity of the WB test; the sensitivity and specificity of the ELISA; the number of live births per 1,000 women; the probability of an infant born to an infected mother being infected; the probability of death in an infected infant; the probability of long-term sequelae in an infected infant.
Study designs and other criteria for inclusion in the review
None of the study designs included in the review were reported. No inclusion or exclusion criteria were specified.
Sources searched to identify primary studies
MEDLINE and the abstracts from "major scientific meetings" were searched for relevant primary studies.
Criteria used to ensure the validity of primary studies
Not reported.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The model input parameters relating to the clinical impact of screening were taken from 34 papers.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The model input parameters relating to the clinical impact of screening were as follows:
the prevalence of infection amongst men was 13%;
the prevalence of infection amongst women was 23%; the annual probability of infection being passed to the male partner was 5%; the annual probability of infection being passed to the female partner was 18%; the probability of symptomatic disease amongst infected individuals was 40%; the average future symptom days amongst men with symptomatic disease was 87; the average future symptom days amongst women with symptomatic disease was 66; the relative risk of infection transmission with regular condom use was 50%;
both the sensitivity and specificity of the WB test were 100%; the sensitivity of the ELISA was 96% and the specificity was 97%; there were between 53 and 114 live births per 1,000 women; the probability of an infant born to an infected mother being infected was 10%; the probability of death in an infected infant was 14%; and the probability of long-term sequelae in an infected infant was 40%.
Measure of benefits used in the economic analysis
Three measures of benefit were used in the economic analysis. These were adult infections averted, symptom days averted, and neonatal infections averted.
Direct costs
The direct costs of the health care provider were included in this study. All appropriate cost elements appear to have been included. The estimates of resource use were derived from the model that provided the clinical effectiveness evidence. The model input parameters were taken from published studies or assumed by the authors. The unit costs were taken from published studies and all unit costs were reported. No specific price year was reported. The costs were appropriately discounted at a rate of 3% per annum.
Statistical analysis of costs
No statistical analysis of the costs was reported.
Indirect Costs
The cost of lost wages due to clinic visits and hospitalisation were estimated using the average US hourly wage rate. The paper did not provide a breakdown of this unit cost and the number of hours lost. No specific price year was reported. The costs were appropriately discounted at a rate of 3% per annum.
